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FDA Approved Pediatric Antihypertensive Agents 
Ashish Doshi 
 
 When choosing a long-term antihypertensive agent in a patient, several factors should 
be considered: Indications or contraindications with respect to co-morbid conditions, side effect 
profile, availability of liquid preparations, dosing interval, and medication cost and generic 
availability.  Knowledge of which agents are FDA-approved and have undergone trials in 
children aids in safe prescribing, but should not prevent one from prescribing an agent not FDA-
approved in children.  This chapter will review major medication classes, mechanism of action, 
representative agents including those approved in children, common or important side effects, 
contraindications, and beneficial populations. 
Diuretics 
 In adults, diuretics have been proven to be as effective as ACE inhibitors or calcium-
channel blockers in preventing fatal coronary heart disease or nonfatal myocardial infarction, 
and perhaps more effective in decreasing blood pressure.1  Thiazide diuretics are one of four 
classes of antihypertensives recommended as first-line therapy for hypertension in adults, the 
other classes being ACE inhibitors, ARBs, and calcium channel blockers.2  Thiazide diuretics 
acutely decrease blood pressure by blocking the sodium-chloride symporter in the distal tubule, 
thus preventing salt and water reabsorption and promoting natriuresis and diuresis.  Loop 
diuretics interfere with the sodium-potassium-chloride cotransporter in the thick ascending limb 
of the loop of Henle, thus causing natriuresis and diuresis.  The long-term antihypertensive 
mechanism of diuretics is less well-understood.  Of the diuretics, only hydrochlorothiazide is 
FDA-approved in children.3  Other diuretics with pediatric experience include chlorthalidone and 
furosemide.  Furosemide is FDA-approved for the treatment of edema but can be used as add-
on therapy for hypertension.  Chlorthalidone can precipitate azotemia and therefore should be 
used with caution in patients with renal disease.  Spironolactone, triamterene, and amiloride are 
potassium-sparing diuretics with pediatric experience.  For all diuretics, electrolytes should be 
monitored periodically, particularly for potassium-sparing diuretics, which can cause 
hyperkalemia, especially when used in conjunction with an ACE inhibitor or ARB. 
ACE inhibitors and ARBs 
 ACE inhibitors are the most-commonly prescribed agents for pediatric hypertension.4  
ACE inhibitors are direct antogonists of angiotensin-converting enzyme, thus reducing the 
conversion of angiotensin I to angiotensin II.  Angiotensin II is a potent vasoconstrictor with the 
greatest vasoconstrictive action on the efferent arteriole versus the afferent arteriole.  
Additionally, it stimulates secretion of aldosterone from the zona glomerulosa cells of the 
adrenal glands and induces release of vasopressin from the pituitary; ACE inhibitors therefore 
decrease blood pressure through a number of mechanisms.  ACE inhibitors can be 
renoprotective in patients with diabetes.5  Benazepril, enalapril, fosinopril, and lisinopril are all 
FDA-approved in children over 6 years of age with creatinine clearance over 30 mL/min per 
1.73 m2.3  Without the action of angiotensin II the afferent arteriole of the glomerulus becomes 
more constricted than the efferent arteriole (or one could say the efferent arteriole becomes 
more dilated as there is no antiotensin II to cause efferent arteriole vasoconstriction).   This 
causes decreased glomerular pressure and in low-volume states such as dehydration or 
ineffective circulating volume (cardio-renal/hepato-renal syndromes) results in acute decreased 
glomerular filtration.  Therefore, adequate intravascular volume must be maintained during ACE 
inhibitor therapy.6,7  Captopril and quinapril also have pediatric experience.  Electrolytes and 
renal function should be monitored periodically as hyperkalemia and azotemia are potential 
risks.  Cough and angioedema are other fairly common side effects: cough reported in up to 
12% of patients; angioedema -1 case per 1000 (0.1%) with captopril and enalapril, 1 case per 
200 (0.5%) with lisinopril.8  Females of childbearing age must have reliable contraception, as 
ACE inhibitors are teratogenic. 
 Angiotensin receptor blockers are similar to ACE inhibitors in their indications.   They 
block the angiotensin II receptor, preventing angiotensin II from causing vasoconstriction or 
release of vasopressin from the pituitary.  The main reason for using an ARB over an ACE 
inhibitor is due to the decreased side effect profile (less incidence of cough and angioedema, 
though hyperkalemia, azotemia, and teratogenicity remain risks).  In theory, because the 
reduction in the amount of circulating angiotensin II due to ACE inhibitors is dose-dependent, 
combination therapy with an ACE inhibitor and an ARB may be more beneficial than using a 
single agent alone.  However, combination therapy has not been found to provide greater 
benefit and at least in the diabetic population has been shown to increase the risk of 
hyperkalemia and acute kidney injury.9  Irbesartan, losartan, and candesartan are all FDA-
approved ARBs in children over 6 years of age with creatinine clearance over 30 mL/min per 
1.73 m2.3 
Beta blockers 
 Beta blockers antagonize the beta adrenergic receptor.  Cardioselective beta blockers 
inhibit beta-1 receptors in the heart and kidney, decreasing inotropy and chronotropy as well as 
renin release.  Non-cardioselective beta blockers inhibit both beta-1 receptors as well as beta-2 
receptors.  Propranolol is the only FDA-approved beta-blocker in children.3  As a non-
cardioselective agent, its use is contraindicated in patients with asthma.  Cardioselective agents 
with pediatric experience include metoprolol and atenolol.  Labetalol is a combined alpha- and 
non-cardioselective beta-blocker and as such should also not be used in patients with asthma.  
The additional peripheral alpha-1 blockade relaxes vascular smooth muscle, aiding in the 
antihypertensive effect.  For all of these medications, bradycardia is the limiting factor in titrating 
up the dose.  In addition, the blunting of appropriate tachycardia may reduce athletic 
performance.  Beta-blockers should not be used in insulin-dependent diabetics as beta-2 
activation stimulates hepatic glycogenolysis, helping to keep blood sugar levels stable. 
Calcium channel blockers 
 Amlodipine is the only FDA-approved calcium channel blocker in children.3  Felodipine, 
isradipine, and extended-release nifedipine also have pediatric experience.  Calcium channel 
blockers inhibit L-type calcium channels in the heart and in vascular smooth muscle.  They 
reduce blood pressure by decreasing myocardial chronotropy and inotropy as well as causing 
arterial and arteriolar dilation.  In all calcium-channel blockers, reflex tachycardia can result from 
peripheral vasodilation. 
Central alpha agonists 
 Clonidine is FDA-approved in children over 12 years.3  It acts as an agonist on central 
alpha-2 receptors in the vasomotor center of the brainstem, thus decreasing norepinephrine 
release and decreasing vascular tone.  In addition to the oral preparation, a transdermal patch 
preparation is available.  Patients should be monitored for anti-cholinergic side effects such as 
dry mouth or sedation.  Suddenly discontinuing the agent can result in severe rebound 
hypertension. 
Peripheral alpha antagonists 
 Doxazosin, prazosin, and terazosin have all been studied in children, though none of 
them are FDA-approved.  These agents inhibit binding of norepinephrine to alpha-1 adrenergic 
receptors on vascular smooth muscle, thus causing vasodilation.  These agents are infrequently 
used, mainly due to available alternative agents with more pediatric experience.  In adults, the 
large ALLHAT study showed that doxazosin was less effective than diuretics at reducing blood 
pressure, and the doxazosin study arm was stopped due to an increased rate of cardiovascular 
disease and congestive heart failure.1  Peripheral alpha antagonists can sometimes cause 
hypotension or syncope when starting therapy. 
Direct vasodilators 
 Hydralazine and minoxidil are both FDA-approved in children.3  Hydralazine activates 
potassium channels in vascular smooth muscle cells, thus hyperpolarizing them and preventing 
the increase in intracellular calcium necessary for smooth muscle contraction.10  Because of the 
direct vasodilation, reflex tachycardia and fluid retention (from increased venous capacitance) 
can be seen.  Minoxidil’s mechanism of action is not well-understood but is thought to largely be 
due to activation of potassium channels10 with a mechanism similar to that of hydralazine.  
Minoxidil is well-known as a topical preparation to treat androgenetic alopecia,11 so one of the 
side effects of oral minoxidil is hypertrichosis.  Hypertrichosis usually resolves 1-6 months after 
stopping therapy. 
Medication 




<6 mos: 2-4mg/kg/day 
>6 mos 1-2 mg/kg/day; 
usually twice daily;  
Max dosing >6mos-2 years= 37.5mg day 
>2 years= 100mg/day 
 
Lisinopril* 
0.7mg/kg/day; usually once daily; 
Max dosing 0.6mg/kg/day up to 40mg/day 
 
Enalapril* 
0.8mg/kg/day; usually twice daily;  
Max dosing 0.6mg/kg/day up to 40mg/day 
 
Candesartan* 
<6 years: 0.2 mg/kg/day 
>6 years <50kg:  4-8 mg daily 
>6 years >50kg: 8-16 mg daily 
usually once daily;  
Max dosing 32 mg/day 
 
Losartan* 0.7 mg/kg/day; usually once daily ;  
Max dosing 1.4 mg/kg/day up to 100 mg/day 
 
Valsartan* 1.3 mg/kg/day; usually once daily; 
Max dosing 2.7 mg/kg/day up to 160mg/day 
Exposure to 
valsartan in 
suspension is 1.6 
times greater than 
the tablet form. 
Propranolol* 1-2 mg/kg/day; usually twice daily; 
Max dosing 8 mg/kg/day up to 640 mg/day 
 
Labetalol 
1-3 mg/kg/day; usually twice daily;  




* = FDA approved in 
pediatric population. 
Dose Comments 
Amlodipine* 2.5 -10 mg/day; once daily dosing;  
Max dosing 10mg 
 
Nifedipine 0.1-0.2 mg/kg/dose; usually given q. 4 hours; 
Max dosing 0.5 mg/kg/dose  








0.05mg once daily; usually give TID;  
Max dosing 0.6 mg/day  
 
 
Applied every 7 days 
 
Doxazosin 1 mg once daily; usually give once daily;  
Max dosing 4mg/day 
 
Hydralazine* 0.75mg/kg/day; usually in 4  divide doses;  
Max dosing 7.5mg/kg or 200mg daily 
 
Minoxidil* 0.2mg/kg/day; usually once daily;  
Max dosing 50mg/day 
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